You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTriamterene
Accession NumberDB00384  (APRD00079)
TypeSmall Molecule
GroupsApproved
Description

A pteridine that is used as a mild diuretic. [PubChem]

Structure
Thumb
Synonyms
6-phenylpteridine-2,4,7-triamine
Dyrenium
Teridin
Triamteren
Triamtérène
Triamterene
Triamtereno
Triamterenum
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dyreniumcapsule50 mg/1oralConcordia Pharmaceuticals Inc.1999-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dyreniumcapsule50 mg/1oralCarilion Materials Management1999-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dyreniumcapsule100 mg/1oralWell Spring Pharmaceutical Corporation1999-01-012020-01-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dyreniumcapsule50 mg/1oralWell Spring Pharmaceutical Corporation1999-10-012019-12-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dyreniumcapsule100 mg/1oralConcordia Pharmaceuticals Inc.1999-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dyrenium 100tablet100 mgoralGlaxosmithkline Inc1992-12-312002-07-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dyrenium 50tablet50 mgoralGlaxosmithkline Inc1992-12-312002-07-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
DiuterenKotobuki Seiyaku
DytacMercury
RiyazineCiiphar
TriterenKyoto Yakuhin
UrinisYing Yuan
Brand mixtures
NameLabellerIngredients
Apo TriazideApotex Inc
DyazideGlaxo Smith Kline Llc
Dyazide TabSmithkline Beecham Pharma Division Of Smithkline Beecham Inc
MaxzideMylan Pharmaceuticals Inc.
Maxzide-25Mylan Pharmaceuticals Inc.
Nu-triazide Tab 50 Mg/25 mgNu Pharm Inc
Penta-triamterene Hctz TabletsPentapharm Ltd.
Pro-triazidePro Doc Limitee
Riva-zide 50/25mg TabletsLaboratoire Riva Inc
Teva-triamterene/hctzTeva Canada Limited
Triamterene and HydrochlorothiazideKAISER FOUNDATION HOSPITALS
Triamterene HydrochlorothiazideKAISER FOUNDATION HOSPITALS
SaltsNot Available
Categories
UNIIWS821Z52LQ
CAS number396-01-0
WeightAverage: 253.2626
Monoisotopic: 253.107593387
Chemical FormulaC12H11N7
InChI KeyInChIKey=FNYLWPVRPXGIIP-UHFFFAOYSA-N
InChI
InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
IUPAC Name
6-phenylpteridine-2,4,7-triamine
SMILES
NC1=NC(N)=C2N=C(C(N)=NC2=N1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pteridines and derivatives. These are polycyclic aromatic compounds containing a pteridine moiety, which consists of a pyrimidine fused to a pyrazine ring to form pyrimido(4,5-b)pyrazine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPteridines and derivatives
Sub ClassNot Available
Direct ParentPteridines and derivatives
Alternative Parents
Substituents
  • Pteridine
  • Aminopyrimidine
  • Aminopyrazine
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Pyrazine
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Hydrocarbon derivative
  • Primary amine
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism.
PharmacodynamicsTriamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium.
Mechanism of actionTriamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.
AbsorptionRapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine.
Volume of distributionNot Available
Protein binding55-67% (93% for the OH-TA-ester metabolite)
Metabolism

Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels.

Route of eliminationNot Available
Half life255 minutes (188 minutes for OH-TA-ester metabolite) after IV administration.
Clearance
  • 4.5 l/min [total plasma clearance]
  • 0.22 l/kg [renal plasma clearance]
ToxicityIn the event of overdosage it can be theorized that electrolyte imbalance would be the major concern, with particular attention to possible hyperkalemia. Other symptoms that might be seen would be nausea and vomiting, other G.I. disturbances, and weakness. It is conceivable that some hypotension could occur. The oral LD50 in mice is 380 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8735
Caco-2 permeable+0.7017
P-glycoprotein substrateNon-substrate0.6269
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8437
CYP450 2C9 substrateNon-substrate0.8949
CYP450 2D6 substrateNon-substrate0.8892
CYP450 3A4 substrateNon-substrate0.7542
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6161
Ames testNon AMES toxic0.8934
CarcinogenicityNon-carcinogens0.9092
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity2.7706 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.6829
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wellspring pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Capsuleoral
Capsuleoral100 mg/1
Capsuleoral50 mg/1
Tabletoral100 mg
Tabletoral50 mg
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point316 °CPhysProp
water solubility48.2 mg/LNot Available
logP0.98HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.963 mg/mLALOGPS
logP1.21ALOGPS
logP1.11ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)15.88ChemAxon
pKa (Strongest Basic)3.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area129.62 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity75.13 m3·mol-1ChemAxon
Polarizability25.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - CI-B (Unknown) , Positivesplash10-00z0000000-c8bbcf103f5a3fdfebb5View in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Frederic J. Nugent, John K. C. Yen, “Process for preparing the combination products of triamterene and hydrochlorothiazide.” U.S. Patent US4804540, issued July, 1987.

US4804540
General References
  1. WellSpring Pharmaceutical Corporation. Dyrenium (triamterene) capsules prescribing information. Neptune, NJ; 2001 June.
  2. Gilfrich HJ, Kremer G, Mohrke W, Mutschler E, Volger KD: Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Eur J Clin Pharmacol. 1983;25(2):237-41. Pubmed
External Links
ATC CodesC03DB02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.5 KB)
Interactions
Drug Interactions
Drug
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Triamterene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Triamterene.
AlfuzosinAlfuzosin may increase the hypotensive activities of Triamterene.
AmifostineTriamterene may increase the hypotensive activities of Amifostine.
Ammonium chlorideThe risk or severity of adverse effects can be increased when Triamterene is combined with Ammonium chloride.
ArdeparinArdeparin may increase the hyperkalemic activities of Triamterene.
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Triamterene.
BenazeprilTriamterene may increase the hyperkalemic activities of Benazepril.
BrimonidineBrimonidine may increase the antihypertensive activities of Triamterene.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Triamterene.
ButabarbitalButabarbital may increase the hypotensive activities of Triamterene.
ButethalButethal may increase the hypotensive activities of Triamterene.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Triamterene.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Triamterene.
CandesartanCandesartan may increase the hyperkalemic activities of Triamterene.
CaptoprilTriamterene may increase the hyperkalemic activities of Captopril.
CelecoxibCelecoxib may decrease the antihypertensive activities of Triamterene.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Triamterene.
CilazaprilTriamterene may increase the hyperkalemic activities of Cilazapril.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.
CyclosporineTriamterene may increase the hyperkalemic activities of Cyclosporine.
DalteparinDalteparin may increase the hyperkalemic activities of Triamterene.
DiazoxideDiazoxide may increase the hypotensive activities of Triamterene.
DiclofenacDiclofenac may decrease the antihypertensive activities of Triamterene.
DiflunisalDiflunisal may decrease the antihypertensive activities of Triamterene.
DigoxinThe therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Triamterene.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Triamterene.
DrospirenoneDrospirenone may increase the hyperkalemic activities of Triamterene.
DuloxetineTriamterene may increase the orthostatic hypotensive activities of Duloxetine.
EnalaprilTriamterene may increase the hyperkalemic activities of Enalapril.
EnalaprilatTriamterene may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Triamterene.
EplerenoneEplerenone may increase the hyperkalemic activities of Triamterene.
EprosartanEprosartan may increase the hyperkalemic activities of Triamterene.
EstradiolEstradiol may increase the hyperkalemic activities of Triamterene.
EtodolacEtodolac may decrease the antihypertensive activities of Triamterene.
FenoprofenFenoprofen may decrease the antihypertensive activities of Triamterene.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Triamterene.
FloctafenineFloctafenine may decrease the antihypertensive activities of Triamterene.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Triamterene.
FosinoprilTriamterene may increase the hyperkalemic activities of Fosinopril.
HeparinHeparin may increase the hyperkalemic activities of Triamterene.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Triamterene.
HexobarbitalHexobarbital may increase the hypotensive activities of Triamterene.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Triamterene.
IbuprofenIbuprofen may decrease the antihypertensive activities of Triamterene.
IndomethacinIndomethacin may decrease the antihypertensive activities of Triamterene.
InfliximabInfliximab may decrease the antihypertensive activities of Triamterene.
IrbesartanIrbesartan may increase the hyperkalemic activities of Triamterene.
KetoprofenKetoprofen may decrease the antihypertensive activities of Triamterene.
KetorolacKetorolac may decrease the antihypertensive activities of Triamterene.
LevodopaTriamterene may increase the orthostatic hypotensive activities of Levodopa.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Triamterene.
LisinoprilTriamterene may increase the hyperkalemic activities of Lisinopril.
LosartanLosartan may increase the hyperkalemic activities of Triamterene.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Triamterene.
MeloxicamMeloxicam may decrease the antihypertensive activities of Triamterene.
MetforminMetformin may increase the hyperkalemic activities of Triamterene.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.
MethohexitalMethohexital may increase the hypotensive activities of Triamterene.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Triamterene.
MoexiprilTriamterene may increase the hyperkalemic activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Triamterene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Triamterene.
MoxonidineMoxonidine may increase the hypotensive activities of Triamterene.
NabumetoneNabumetone may decrease the antihypertensive activities of Triamterene.
NadroparinNadroparin may increase the hyperkalemic activities of Triamterene.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Triamterene.
NaproxenNaproxen may decrease the antihypertensive activities of Triamterene.
NicorandilNicorandil may increase the hypotensive activities of Triamterene.
ObinutuzumabTriamterene may increase the hypotensive activities of Obinutuzumab.
OlmesartanOlmesartan may increase the hyperkalemic activities of Triamterene.
OxaprozinOxaprozin may decrease the antihypertensive activities of Triamterene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Triamterene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Triamterene.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Triamterene.
PentobarbitalPentobarbital may increase the hypotensive activities of Triamterene.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Triamterene.
PerindoprilTriamterene may increase the hyperkalemic activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Triamterene.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Triamterene.
PiroxicamPiroxicam may decrease the antihypertensive activities of Triamterene.
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Triamterene.
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Triamterene.
Potassium IodidePotassium Iodide may increase the hyperkalemic activities of Triamterene.
PrimidonePrimidone may increase the hypotensive activities of Triamterene.
QuinaprilTriamterene may increase the hyperkalemic activities of Quinapril.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Triamterene.
QuinineQuinine may increase the hypotensive activities of Triamterene.
RamiprilTriamterene may increase the hyperkalemic activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.
RisperidoneTriamterene may increase the hypotensive activities of Risperidone.
RituximabTriamterene may increase the hypotensive activities of Rituximab.
SecobarbitalSecobarbital may increase the hypotensive activities of Triamterene.
SpironolactoneTriamterene may increase the hyperkalemic activities of Spironolactone.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.
SulindacSulindac may decrease the antihypertensive activities of Triamterene.
TacrolimusTriamterene may increase the hyperkalemic activities of Tacrolimus.
TadalafilTadalafil may increase the antihypertensive activities of Triamterene.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triamterene.
TelmisartanTelmisartan may increase the hyperkalemic activities of Triamterene.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Triamterene.
TinzaparinTinzaparin may increase the hyperkalemic activities of Triamterene.
TolmetinTolmetin may decrease the antihypertensive activities of Triamterene.
TolvaptanTolvaptan may increase the hyperkalemic activities of Triamterene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.
TrandolaprilTriamterene may increase the hyperkalemic activities of Trandolapril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Triamterene.
TreprostinilTreprostinil may increase the hypotensive activities of Triamterene.
ValsartanValsartan may increase the hyperkalemic activities of Triamterene.
VardenafilVardenafil may increase the antihypertensive activities of Triamterene.
YohimbineYohimbine may decrease the antihypertensive activities of Triamterene.
Food InteractionsNot Available

Targets

1. Amiloride-sensitive sodium channel subunit gamma

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Amiloride-sensitive sodium channel subunit gamma P51170 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Hiraoka Y, Taniguchi T, Tanaka T, Okada K, Kanamaru H, Muramatsu I: Pharmacological characterization of unique prazosin-binding sites in human kidney. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jul;368(1):49-56. Epub 2003 Jun 25. Pubmed
  4. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes – underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. Pubmed
  5. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. Pubmed

2. Amiloride-sensitive sodium channel subunit alpha

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Amiloride-sensitive sodium channel subunit alpha P37088 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes – underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. Pubmed
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. Pubmed
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Amiloride-sensitive sodium channel subunit beta

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Amiloride-sensitive sodium channel subunit beta P51168 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Busch AE, Suessbrich H, Kunzelmann K, Hipper A, Greger R, Waldegger S, Mutschler E, Lindemann B, Lang F: Blockade of epithelial Na+ channels by triamterenes – underlying mechanisms and molecular basis. Pflugers Arch. 1996 Sep;432(5):760-6. Pubmed
  4. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. Pubmed

4. Amiloride-sensitive sodium channel subunit delta

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Amiloride-sensitive sodium channel subunit delta P51172 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Broer S, Moschen I, Albers A, Waldegger S, Tummler B, Egan ME, Geibel JP, Kandolf R, Lang F: Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. Pubmed

Enzymes

1. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 12, 2014 21:01